Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Estrogen Receptor Positive Tumor|Menopause|Hormone Antagonist
Interventions: DRUG: Immune-attractant|DRUG: Durvalumab|PROCEDURE: Biopsy
Sponsor: UNICANCER
Collaborators: Breast International Group